세계의 프로트롬빈 복합체 농축물 시장 보고서(2025년)
Prothrombin Complex Concentrate Global Market Report 2025
상품코드 : 1751087
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,493,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,386,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,279,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

프로트롬빈 복합체 농축물 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 연평균 7.6%의 성장률(CAGR)로 18억 6,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 신속한 응고 요법에 대한 수요 증가, 혈우병 및 간 질환의 유병률 증가, 응급 의료 분야에서의 사용 증가, 심장 수술에서의 사용 확대, 의료 지출 증가 등의 요인에 기인합니다. 이 기간의 주요 동향으로는 AI 기반 진단의 통합, 유전자재조합 응고인자의 발전, 차세대 유전자재조합 PCC, 맞춤형 투여 알고리즘, 혈장 제제의 발전 등이 있습니다.

출혈성 질환의 유병률 증가는 향후 몇 년 동안 프로트롬빈 복합체 농축물 시장의 성장을 촉진할 것으로 예상됩니다. 출혈성 질환은 혈액이 제대로 응고되지 않고 응고인자나 혈소판의 결핍 또는 기능 장애로 인해 과도한 출혈을 유발하는 질환입니다. 출혈성 질환의 증가는 주로 혈우병과 같은 유전성 질환의 유병률 증가, 간 질환 사례의 증가, 항응고제의 광범위한 사용, 비타민 K 결핍증의 비율 증가 등에 기인합니다. 프로트롬빈 복합체 농축물은 혈액 응고 및 지혈에 필수적인 응고인자를 신속하게 보충하여 출혈성 질환 관리에 도움을 줄 수 있습니다. 예를 들어, 2023년 11월 미국 국립의학도서관(National Library of Medicine)은 2022년 40개국 87개 치료센터에서 수행된 연구를 보고했습니다. 이 조사에는 1,276명의 혈우병 환자들이 참여했으며, 49%는 중증 혈우병 환자였습니다. 참가자 대부분(99%)은 남성이었고, 85%는 혈우병 A형이었습니다. 또한, 환자의 67%는 중저소득 국가 출신이었습니다. 따라서 출혈성 질환의 유병률 증가는 프로트롬빈 복합체 농축물 시장의 중요한 촉진제입니다.

항응고제 처방률의 증가는 프로트롬빈 복합체 농축물 시장의 성장을 더욱 촉진할 것으로 예상됩니다. 항응고제는 응고인자 및 혈소판 응집을 억제하여 혈전 형성을 예방 및 억제하는 물질입니다. 항응고제 처방 증가는 주로 심혈관질환의 유병률 증가, 고령화, 광범위한 임상 적응증, 스크리닝 프로그램 개선, 항응고 요법의 발전으로 인해 발생합니다. 프로트롬빈 복합체 농축물은 과도한 출혈을 경험하거나 긴급한 외과적 개입이 필요한 환자에서 응고인자를 신속하게 보충하고 지혈을 회복하여 항응고제의 효과를 상쇄하는 데 도움이 될 수 있습니다. 예를 들어, 2023년 11월 영국 정부 기관인 국민보건서비스(NHS)는 2022년에 46만 명이 새로 항응고제를 사용하기 시작했으며, 2,400만 건 이상의 처방전이 환자에게 발급되었다고 보고했습니다. 이를 통해 약 17,000명의 뇌졸중과 4,000명의 사망을 예방할 수 있을 것으로 추정됩니다. 그 결과, 항응고제 처방률의 증가가 프로트롬빈 복합체 농축물 시장의 성장에 기여하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

ksm
영문 목차

영문목차

Prothrombin complex concentrate (PCC) is a medication that contains clotting factors, used to treat or prevent bleeding in patients with coagulation disorders. It is administered intravenously to quickly restore clotting factor levels in conditions such as hemophilia, warfarin reversal, and severe bleeding episodes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main types of prothrombin complex concentrate products include 3-factor prothrombin complex concentrates (3F-PCC), 4-factor prothrombin complex concentrates (4F-PCC), and other variations. 3-factor prothrombin complex concentrates (3F-PCC) are blood products containing clotting factors II, IX, and X, used to manage bleeding without the need for factor VII supplementation. These are indicated for conditions such as hemorrhagic episodes in factor IX deficiency (hemophilia B), trauma, life-threatening coagulopathy with acute bleeding, warfarin-associated acute life-threatening bleeding, and non-warfarin anticoagulant reversal during acute bleeding. The routes of administration include intravenous (IV), subcutaneous, and intramuscular injections, with usage in hospitals, ambulatory surgical centers, specialty clinics, and other healthcare facilities.

The prothrombin complex concentrate market research report is one of a series of new reports from The Business Research Company that provides prothrombin complex concentrate market statistics, including the prothrombin complex concentrate industry global market size, regional shares, competitors with the prothrombin complex concentrate market share, detailed prothrombin complex concentrate market segments, market trends, and opportunities, and any further data you may need to thrive in the prothrombin complex concentrate industry. This prothrombin complex concentrate market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The prothrombin complex concentrate market size has grown strongly in recent years. It will grow from$1.29 billion in 2024 to $1.39 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth during the historic period can be attributed to factors such as the rising prevalence of bleeding disorders, increased use of PCC in warfarin reversal, greater awareness of coagulation therapies, expansion of surgical procedures, and a higher number of trauma cases.

The prothrombin complex concentrate market size is expected to see strong growth in the next few years. It will grow to$1.86 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth during the forecast period can be attributed to factors such as the growing demand for rapid coagulation therapies, the increasing prevalence of hemophilia and liver diseases, rising adoption in emergency medicine, expanding applications in cardiac surgeries, and higher healthcare expenditures. Key trends during this period include the integration of AI-driven diagnostics, advancements in recombinant coagulation factors, next-generation recombinant PCCs, customized dosing algorithms, and progress in blood plasma products.

The growing prevalence of bleeding disorders is anticipated to drive the expansion of the prothrombin complex concentrate market in the coming years. Bleeding disorders are conditions in which blood does not clot properly, leading to excessive bleeding due to missing or malfunctioning clotting factors or platelets. The rise in bleeding disorders is mainly attributed to the increasing prevalence of genetic conditions such as hemophilia, more cases of liver diseases, the wider use of anticoagulant medications, and higher rates of vitamin K deficiencies. Prothrombin complex concentrate helps manage bleeding disorders by quickly replenishing the clotting factors essential for blood coagulation and hemostasis. For example, in November 2023, a U.S.-based medical library, the National Library of Medicine, reported a study conducted in 2022 across 87 treatment centers in 40 countries. This study involved 10,276 individuals with hemophilia, with 49% of participants having severe hemophilia. The majority (99%) of the participants were male, and 85% had hemophilia A. Additionally, 67% of the patients were from low- and middle-income countries. Thus, the increasing prevalence of bleeding disorders is a significant driver for the prothrombin complex concentrate market.

The rising prescription rate of anticoagulants is expected to further boost the growth of the prothrombin complex concentrate market. Anticoagulants are substances that prevent or reduce blood clot formation by inhibiting coagulation factors or platelet aggregation. The increased prescription of anticoagulants is primarily driven by the growing prevalence of cardiovascular diseases, an aging population, broader clinical indications, better screening programs, and advancements in anticoagulant therapy. Prothrombin complex concentrate helps counteract the effects of anticoagulants by quickly replenishing clotting factors and restoring hemostasis in patients experiencing excessive bleeding or requiring urgent surgical intervention. For instance, in November 2023, the National Health Service (NHS), a UK-based government body, reported that in 2022, 460,000 additional people began using anticoagulant medications, with over 24 million prescriptions issued to patients. This helped prevent an estimated 17,000 strokes and 4,000 deaths. Consequently, the increasing prescription rate of anticoagulants is contributing to the growth of the prothrombin complex concentrate market.

Leading companies in the prothrombin complex concentrate market are developing innovative formulations, such as lyophilized powder, to improve stability, enhance storage, and simplify administration. The lyophilized powder is a freeze-dried formulation that removes water to extend shelf life while maintaining potency. This enables better storage conditions and rapid reconstitution for emergency use. For example, in July 2023, Octapharma USA Inc., a biotechnology company based in the U.S., received FDA approval for Balfaxar, a four-factor prothrombin complex concentrate (4F-PCC) for the urgent reversal of warfarin during surgeries and invasive procedures. The approval was based on the results from the LEX-209 trial, which demonstrated 94.6% hemostatic efficacy, proving it to be as effective as Kcentra. This development highlights the industry's focus on advancing coagulation therapies to improve patient outcomes in critical care environments.

Major players in the prothrombin complex concentrate market are Pfizer Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, CSL Behring GmbH, Intas Pharmaceuticals Ltd, Baxter International Inc, Grifols S.A., Octapharma AG, Kedrion S.p.A, Haemonetics Corporation, Green Cross Corporation, Shanghai RAAS Blood Products Co. Ltd, Emergent BioSolutions, LFB Group, Hualan Biological Engineering Chongqing Co. Ltd., Sanquin Blood Supply Foundation, Bio Products Laboratory Ltd (BPL), Prothya Biosolutions B.V., and China Biologic Products Holdings Inc.

North America was the largest region in the prothrombin complex concentrate market in 2024. The regions covered in prothrombin complex concentrate report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the prothrombin complex concentrate market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The prothrombin complex concentrate market consists of sales of activated PCC, recombinant coagulation factors, combination hemostatic agents, warfarin reversal, and emergency coagulation therapy products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Prothrombin Complex Concentrate Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on prothrombin complex concentrate market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for prothrombin complex concentrate ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The prothrombin complex concentrate market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Prothrombin Complex Concentrate Market Characteristics

3. Prothrombin Complex Concentrate Market Trends And Strategies

4. Prothrombin Complex Concentrate Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Prothrombin Complex Concentrate Growth Analysis And Strategic Analysis Framework

6. Prothrombin Complex Concentrate Market Segmentation

7. Prothrombin Complex Concentrate Market Regional And Country Analysis

8. Asia-Pacific Prothrombin Complex Concentrate Market

9. China Prothrombin Complex Concentrate Market

10. India Prothrombin Complex Concentrate Market

11. Japan Prothrombin Complex Concentrate Market

12. Australia Prothrombin Complex Concentrate Market

13. Indonesia Prothrombin Complex Concentrate Market

14. South Korea Prothrombin Complex Concentrate Market

15. Western Europe Prothrombin Complex Concentrate Market

16. UK Prothrombin Complex Concentrate Market

17. Germany Prothrombin Complex Concentrate Market

18. France Prothrombin Complex Concentrate Market

19. Italy Prothrombin Complex Concentrate Market

20. Spain Prothrombin Complex Concentrate Market

21. Eastern Europe Prothrombin Complex Concentrate Market

22. Russia Prothrombin Complex Concentrate Market

23. North America Prothrombin Complex Concentrate Market

24. USA Prothrombin Complex Concentrate Market

25. Canada Prothrombin Complex Concentrate Market

26. South America Prothrombin Complex Concentrate Market

27. Brazil Prothrombin Complex Concentrate Market

28. Middle East Prothrombin Complex Concentrate Market

29. Africa Prothrombin Complex Concentrate Market

30. Prothrombin Complex Concentrate Market Competitive Landscape And Company Profiles

31. Prothrombin Complex Concentrate Market Other Major And Innovative Companies

32. Global Prothrombin Complex Concentrate Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Prothrombin Complex Concentrate Market

34. Recent Developments In The Prothrombin Complex Concentrate Market

35. Prothrombin Complex Concentrate Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기